A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

[1]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[2]  L. Staudt,et al.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. , 2012, Blood.

[3]  M. Kalos,et al.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. , 2013, The American journal of pathology.

[4]  Sumit Middha,et al.  Novel TRAF1‐ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma , 2013, Genes, chromosomes & cancer.

[5]  A. Rosenwald,et al.  PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. , 2013, Blood.

[6]  G. Gaidano,et al.  Genome‐wide high resolution DNA profiling of hairy cell leukaemia , 2013, British journal of haematology.

[7]  L. Meltesen,et al.  Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma , 2013, Journal of pediatric hematology/oncology.

[8]  S. Pileri,et al.  Abstract 3853: Humanized NOD/Scid/IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma. , 2013 .

[9]  D. Rossi,et al.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia , 2012, Haematologica.

[10]  S. Pileri,et al.  PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas , 2012, Nature Medicine.

[11]  D. Greiner,et al.  Humanized mice for immune system investigation: progress, promise and challenges , 2012, Nature Reviews Immunology.

[12]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[13]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[14]  Enrico Macii,et al.  Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model , 2012, Bioinform..

[15]  Francesco Bertoni,et al.  Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. , 2012, Blood.

[16]  K. Savage,et al.  Anaplastic large cell lymphoma, ALK-positive. , 2012, Critical reviews in oncology/hematology.

[17]  J. Cigudosa,et al.  Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia , 2011, Leukemia.

[18]  Aik Choon Tan,et al.  Patient-derived tumour xenografts as models for oncology drug development , 2012, Nature Reviews Clinical Oncology.

[19]  G. Inghirami,et al.  ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma , 2012, Front. Oncol..

[20]  R. Palmer,et al.  Anaplastic lymphoma kinase in human cancer. , 2012, Critical reviews in oncogenesis.

[21]  J. Cigudosa,et al.  Preclinical activity of LBH 589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia , 2012 .

[22]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP 63 and other p 53-related genes in peripheral T-cell lymphomas Running head : Genome-wide analysis of T-cell lymphomas , 2012 .

[23]  G. Inghirami,et al.  CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers , 2011, Molecular Cancer Therapeutics.

[24]  Christopher A. Maher,et al.  ChimeraScan: a tool for identifying chimeric transcription in sequencing data , 2011, Bioinform..

[25]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[26]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[27]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011 .

[28]  H. Moritake,et al.  C‐MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C‐MYC , 2011, American journal of hematology.

[29]  A. Rosenwald,et al.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.

[30]  N. Amariglio,et al.  TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function , 2010, The Journal of Immunology.

[31]  Enzo Medico,et al.  Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M Paulli,et al.  Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma , 2009, Leukemia.

[33]  B. Falini,et al.  Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy , 2009, Haematologica.

[34]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[35]  K. Anderson,et al.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. , 2009, Blood.

[36]  J. Nardone,et al.  The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. , 2009, Blood.

[37]  K. Garber.  From human to mouse and back: 'tumorgraft' models surge in popularity. , 2009, Journal of the National Cancer Institute.

[38]  G. Roodman,et al.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. , 2008, Blood.

[39]  M. Djokic.  ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project , 2009 .

[40]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[41]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[42]  J. Tao,et al.  Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells , 2007, Leukemia.

[43]  Lauren B. Smith,et al.  Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature , 2007, Annals of Hematology.

[44]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[45]  S. Monaco,et al.  Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phase , 2007, American journal of hematology.

[46]  Michael Q. Zhang,et al.  TRED: a transcriptional regulatory element database, new entries and other development , 2007, Nucleic Acids Res..

[47]  J. Tao,et al.  Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. , 2007, Leukemia.

[48]  Limin Fu,et al.  FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data , 2007, BMC Bioinformatics.

[49]  R. Hruban,et al.  An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.

[50]  M. Pierotti,et al.  The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF‐κB pathway , 2006, Journal of cellular physiology.

[51]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[52]  R. Taulli,et al.  Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. , 2006, Blood.

[53]  H. Stein,et al.  Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .

[54]  J. Benítez,et al.  Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas , 2005, Leukemia.

[55]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Golub,et al.  NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. , 2005, Blood.

[57]  H. Stein,et al.  Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. , 2005, Blood.

[58]  Toshiki Watanabe,et al.  The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. , 2004, Cancer cell.

[59]  P. Marynen,et al.  Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor , 2002, Genes, chromosomes & cancer.

[60]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[61]  R. Siebert,et al.  Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. , 2000, Blood.

[62]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.